AstraZeneca collaborates with Multiply Labs to scale cell therapy manufacturing using end-to-end GMP-ready robotic technology.

Biomanufacturing company Multiply Labs is using Nvidia technologies to develop robotic biomanufacturing systems for ...

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...

Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of-concept ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...

Multiply Labs' leverage of NVIDIA’s tech stack marks a turning point for a biomanufacturing industry that has historically relied on manual, "artisanal" processes. By integrating NVIDIA’s digital ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is ...